Task: Answer the following question about the molecule with SMILES O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO.
Description: Please describe this drug.
Result: Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T cell lymphoma. Belinostat is associated with moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury.
Task: Answer the following question about the molecule with {SMILES__description} {SMILES#}.
{#Description|Question|Request!}: {quest#}
{#Result|Answer|Completion!}: {answ#}
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO
C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)/C=C/C(=O)NO
(E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
Please describe this drug.
Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T cell lymphoma. Belinostat is associated with moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury.